Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

Rhea-AI Summary

Pasithea Therapeutics (NASDAQ: KTTA) has announced its participation in the upcoming 2025 CAGLA NeauxCancer Conference, a leading global oncology forum scheduled for March 27-29, 2025, in New Orleans.

The company's Vice President of Business Development, Mathew Lazarus, will present on March 28 at 11:00 AM CDT at The Roosevelt Hotel. His presentation will focus on PAS-004, the company's next-generation macrocyclic MEK inhibitor being developed for neurofibromatosis type 1 (NF1) and other cancer indications.

The presentation will include interim data from their ongoing Phase 1 study, covering safety, tolerability, and pharmacokinetic (PK) results in advanced cancer patients with MAPK pathway-driven tumors. Lazarus will also discuss Pasithea's progress in clinical development and their strategy to revolutionize cancer and NF1 treatment.

-- Conference taking place on March 27-29, 2025 in New Orleans --

-- CAGLA NeauxCancer Conference is a leading global forum in oncology --

MIAMI, March 24, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced its Vice President of Business Development, Mathew Lazarus, will be presenting at the 2025 Cancer Advocacy Group of Louisiana ("CAGLA") NeauxCancer Conference taking place on March 27-29, 2025 at the The Roosevelt Hotel in New Orleans.

Mr. Lazarus’s presentation will provide an overview of Pasithea’s next generation macrocyclic MEK inihibitor, PAS-004, including interim safety, tolerability and pharmacokinetic (PK) data from the Company’s ongoing open-label dose escalation Phase 1 study in advanced cancer patients with MAPK pathway-driven advanced tumors. He will discuss the Company's latest progress in clinical development and how Pasithea is advancing its next-generation molecule to transform cancer and NF1 treatment.

Details of the presentation are as follows:

Event: 2025 CAGLA NeauxCancer Conference
Date: March 28, 2025
Time: 11:00 AM CDT
Location: The Roosevelt New Orleans
Webcast: CAGLA 2025 Livestreams

The CAGLA NeauxCancer Conference is a premier gathering of leading oncology researchers, industry executives, and medical professionals focused on groundbreaking developments in cancer treatment and care.

For more information about the conference, visit https://cag-la.org/neauxcancer-2025/.

About Pasithea Therapeutics Corp.

Pasithea is a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. With an experienced team of experts in the fields of neuroscience, translational medicine, and drug development, Pasithea is developing new molecular entities for the treatment of neurological disorders, including Neurofibromatosis type 1 (NF1), Solid Tumors, and Amyotrophic Lateral Sclerosis (ALS). For more information, visit www.pasithea.com.

Pasithea Therapeutics Contact

Patrick Gaynes
Corporate Communications
pgaynes@pasithea.com

FAQ

What will Pasithea Therapeutics (KTTA) present at the 2025 CAGLA NeauxCancer Conference?

KTTA will present interim data from their Phase 1 study of PAS-004, including safety, tolerability, and pharmacokinetic results in advanced cancer patients.

When and where is KTTA's presentation at the 2025 CAGLA Conference?

The presentation is scheduled for March 28, 2025, at 11:00 AM CDT at The Roosevelt Hotel in New Orleans.

What medical conditions is KTTA's PAS-004 being developed to treat?

PAS-004 is being developed for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications.

What type of drug is Pasithea's (KTTA) PAS-004?

PAS-004 is a next-generation macrocyclic MEK inhibitor targeting MAPK pathway-driven advanced tumors.

What clinical stage is KTTA's PAS-004 currently in?

PAS-004 is currently in an open-label dose escalation Phase 1 study for advanced cancer patients.